(Q73712793)

English

HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia

scientific article published on 01 May 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

mixed hyperlipidemia

1 reference

based on heuristic

inferred from title

author name string

K Winkler

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

J R Schaefer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

B Klima

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

C Nuber

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

I Friedrich

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

W Köster

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

H Gierens

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

H Scharnagl

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

M Soufi

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

H Wieland

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

W März

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

publication date

1 May 2000

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Atherosclerosis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

150

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

113-120

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

High-density lipoprotein--the clinical implications of recent studies

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women

2 references

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Lifibrol: first member of a new class of lipid-lowering drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Subjects with ApoA-I(Lys107-->0) exhibit enhanced fractional catabolic rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI with AII)

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-I and A-II fractional catabolic rate in women

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Mechanism of action of gemfibrozil on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2).

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Cholesterol transport between cells and high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Apolipoprotein function in health and disease: insights from natural mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Effects of deletion of the carboxyl-terminal domain of ApoA-I or of its substitution with helices of ApoA-II on in vitro and in vivo lipoprotein association.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

Homozygous Tangier disease and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

HDL metabolism in HDL deficiency associated with familial hypertriglyceridemia: effect of treatment with gemfibrozil

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2899%2900351-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0021-9150(99)00351-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10781641%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73712793&oldid=2004940272"